World Heart Day, occuring on the 29th of September, spotlights the need to develop major researches related to cardiovascular diseases. In this context stands out the emerging role of HMGB1 in cardiovascular health, particularly in relation to heart disease and inflammation.
LPS-free HMGB1 proteins allow for safe and accurate in vitro and in vivo researches, in order to go deeper in heart-related diseases.
A recent research has shown how serum HMGB1 levels are increased in acute myocardial infarction (AMI) patients, with or without accompanying heart failure (HF).
High HMGB1 levels were especially prominent in AMI patients who also had heart failure, reinforcing its importance in identifying high-risk patients.
Furthermore, another study has highlighted the HMGB1/RAGE axis in the development of atherosclerosis, a major cause of heart disease. The compound 3′-Sialyllactose (3′-SL), derived from human milk oligosaccharides, was found to protect against LPS-induced endothelial dysfunction by inhibiting the HMGB1/RAGE pathway. This suggests a new therapeutic approaches targeting HMGB1 to prevent heart-related complications.
We are specialized in the production of LPS-free proteins. Our LPS-free product range includes: Disulfide HMGB1, Non-oxidizable chemokine-HMGB1, and Fully reduced HMGB1 and Terminally oxidized HMGB1.
Contact us for your pre-sales questions about HMGB1
Read the full articles about the studies:
https://pubmed.ncbi.nlm.nih.gov/38191050/
https://pubmed.ncbi.nlm.nih.gov/37775976/
